ArticlePloS one2021
The Science for Profit Model-How and why corporations influence science and the use of science in policy and practice.
Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 1 synthesis or guideline pooled it, 120 citations in OpenAlex.
- Impact of heated tobacco products on biomarkers of potential harm and adverse events: a systematic review and meta-analysis.Tobacco control · 2026Pooled it
- The influence of the pharmaceutical industry and the pharmacy sector on Aboriginal and Torres Strait Islander health: a yarning study.Health promotion international · 2026Article
- Tobacco industry influence on breast cancer research, policy and public opinion: scoping the Truth Tobacco Industry Documents.Tobacco control · 2026Article
- Defining the commercial tobacco industry in a changing nicotine landscape.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2026Article
- Food industry's interactions with nutrition professionals in Australia: a survey.Public health nutrition · 2026Article
- Indigenous excellence: confronting racism and complicity in peer review.Health promotion international · 2026Article
- Digital vectors of disease: how alcohol 'smart' labels leapfrog health policy.BMC public health · 2026Article
- Reviewing ecosystems of evidence: synthesising the evidence on the commercial determinants of health from a complex systems perspective.Systematic reviews · 2026Article
- A portrait of commissioned literature: connecting the dots between medical education and communication companies, authors, funders and publishers.Research integrity and peer review · 2026Article
- Independent companies in the tobacco supply chain: transparency and environmental social governance.Tobacco control · 2026Article
- Scientific Meetings in Medical Oncology: Are We Facing a Time- and Resource-Consuming Plethora?Current oncology (Toronto, Ont.) · 2026Article
- Public policies addressing unhealthy diets in the South-East Asia region: identifying and countering the arguments that undermine policy implementation.Health policy and planning · 2026Article
- Article
- The Corporate Political Activity of the infant commercial milk formula industry in Mexico during the COVID-19 pandemic.International breastfeeding journal · 2025Article
- Constructing and contesting industry's role in multistakeholder governance: a qualitative analysis of responses to WHO consultations.Globalization and health · 2025Article
- Adverse commercial determinants of health in low- and middle-income countries: a public health challenge.Health promotion international · 2025Article
- 'Playing to extinction': the commercial determinants of gambling-related harm, suicidality and suicide.The Lancet regional health. Western Pacific · 2025Review
- Oversimplification of a complex public health issue that serves exploitative industry interests.Addiction (Abingdon, England) · 2025Article
- How governments influence public health research: a scoping review.Health promotion international · 2025Article
- Why addressing conflicts of interest is essential to progress in reducing commercially driven health harms: Lessons from tobacco.Future healthcare journal · 2025Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Science has been at the centre of attempts by major industries, including tobacco, chemical, and pharmaceutical, to delay progress in tackling threats to human and planetary health by, inter alia, obscuring industry harms, and opposing regulation. Some aspects of this influence are well documented, others remain poorly understood, and similarities between industries remain underexplored. This study, therefore, aims to synthesise the literature to develop an evidence-based typology and model of corporate influence on science in order to provide an overview of this multi-faceted phenomenon. We obtained literature examining corporate attempts to influence science and the use of science in policy and practice from: database searches, bibliographies, expert recommendations, and web alerts; using a modified scoping review methodology (n = 68). Through interpretive analysis we developed the Science for Profit Typology and Model. We identified eight corporate sectors repeatedly engaging in activities to influence science, including: manipulation of scientific methods; reshaping of criteria for establishing scientific "proof"; threats against scientists; and clandestine promotion of policy reforms that increase reliance on industry evidence. The typology identifies five macro-level strategies used consistently across the eight industries, comprising 19 meso-level strategies. The model shows how these strategies work to maximise the volume, credibility, reach, and use of industry-favourable science, while minimising these same aspects of industry-unfavourable science. This creates doubt about harms of industry products/practices or efficacy of policies affecting industry; promotes industry-favoured policy responses and industry products as solutions; and legitimises industry's role as scientific stakeholder. These efforts ultimately serve to weaken policy, prevent litigation, and maximise use of industry products/practices-maximising corporate profitability. We provide an accessible way to understand how and why corporations influence science, demonstrate the need for collective solutions, and discuss changes needed to ensure science works in the public interest.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.